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Summary To study the possible involvement of mouse mammary tumour virus (MMTV) related agent in
human cancer we analysed 300 samples of human sera for the presence of antibodies to MMTV structural
proteins. All sera were tested by immunoblotting to achieve high specificity. Out of 300 sera, 22 reacted with
transframe protein p30, 16 with the ribonucleoprotein p14, six with the envelope glycoprotein gp52 and three
with the major core protein p27. Reactivities to p30 and p14 were observed in sera from cancer patients and
healthy controls; reactivities to p27 and gp52 predominated in sera of cancer patients. Sera frequently reacted
with a 42 kDa protein which is a cellular contaminant of the virus.
Mouse mammary tumour virus has been reported to be an
aetiological agent of most mammary gland tumours, some
lymphomas and renal carcinomas in mice (for review see
Salmons & Giinzburg, 1987). Although it is a very suitable
model of carcinogenesis in mice no such role for MMTV-like
species has been demonstrated for human breast cancer.
Antigens immunologically related to MMTV proteins have
been found in human breast cancer tissues as well as in
various mammary cancer cell lines. Retrovirus-like particles
were purified from culture media of human mammary cell
line T47D. Antigen immunologically related to MMTV gp52
was detected in viral preparations and also in a soluble form
in culture media (Keydar et al., 1984). Reverse transcriptase
activity associated with retrovirus-like particles has recently
been reported in monocytes from breast cancer patients (Al-
Sumidaie et al., 1988). There exists a vast literature concern-
ing the presence of antibodies of MMTV proteins in sera of
breast cancer patients (see e.g. Witkin et al., 1980; Day et al.,
1981; Tomana et al., 1981; Holder & Wells, 1983; Zotter et
al., 1983; Dion et al., 1987). However, the specificity of the
antibodies used in these studies has been controversial. These
studies frequently used enzyme-linked immunoadsorbent ass-
ays (ELISA) and cellular immunofluorescence (CIF). Such
techniques cannot accurately distinguish specific and non-
specific reactions of sera. Some authors believe that most
reactiveness of human sera against viral proteins could be
accounted for by heterophilic antibodies that bind the carbo-
hydrate moieties of viral glycoproteins (Barbacid et al., 1980;
Snyder & Fleissner, 1980). Nevertheless, human sera have
been reported to react with core MMTV proteins using
radioimmunoprecipitation (RIP) and ELISA with purified
MMTV proteins (Zotter et al., 1983; Dion et al., 1987). In
addition, human-human hybridoma cell lines derived from
lymph nodes of breast cancer have been reported which
produce monoclonal antibodies against MMTV proteins
(Shoenfeld et al., 1987). Molecular cloning techniques have
revealed the presence of numerous nucleotide sequences re-
lated to the MMTV genome in human DNA (Callahan et al.,
1982; Deen & Sweet, 1986; Ono et al., 1986; Franklin et al.,
1988). All human endogenous retroviruses studied so far are
defective or incomplete although some contain functional
LTR and even long open reading frames. Their transcripts
have been detected in various cancer cell lines and also in
normal human placenta. Enhanced transcription upon the
steroid treatment was shown in the T47D breast cancer cell
line and for the transcripts of the NMWV 4 family (Ono et
al., 1987; Franklin et al., 1988).
The purpose of this study is to demonstrate the presence
of specific antibodies to MMTV proteins in human sera.
Immunoblotting is an excellent technique for distinguishing
specific and non-specific reactions. The possible source of
non-specific reactions and the frequency of specific antibodies
to MMTV in the sera of cancer patients and healthy controls
are discussed.
Materials and methods
Sera
Samples of sera from cancer patients were obtained from the
Institute of Clinical Oncology, Bratislava. Sera of patients
with autoimmune diseases were from the Faculty Hospital of
the Faculty of Medicine, Bratislava. Reference sera of
acquired immunodeficiency syndrome (AIDS) patients were
generous gifts of Prof. J.C. Cherman from Institut Pasteur,
Paris and Prof. A. Vaheri from University of Helsinki. Sera
of healthy donors were mostly from healthy workers of the
Cancer Research Institute, Bratislava. Sera from breast can-
cer patients were taken one or two days before resection of
the tumour. The most common histological type of tumour
was infiltrating ductal mammary carcinoma at grades 11 and
Ill. Sera from patients with other malignancies were used
irrespective of the stage or treatment. All sera except those of
AIDS patients were human immunodeficiency virus (HIV)
negative. Sera were kept frozen at -20°C until use.
Source of the viruses
GR/N cells grown in RPMI 1640 medium containing 5%
fetal calf serum produced MMTV upon dexamethasone treat-
ment. Bovine leukaemia virus (BLV) was produced by FLK
cells. Avian myeloblastosis virus (AMV) was purified from
plasma of infected chickens. Murine leukaemia virus strain
Rauscher (Ra-MuLV) was a gift of Dr Gruber from NCI,
Bethesda. All retroviruses were purified by isopycnic sucrose
gradient centrifugation.
Electrophoresis andprotein hlotting
Viral proteins were separated in sodium dodecyl sulphate
polyacrylamide gradient (5-22%) slab gel (SDS-PAGE)
(Laemmli, 1970). Electrophoretic transfer to nitrocellulose
sheets (0.45 gm, Schleicher & Schuell) was performed accord-
ing to Bittner et al., (1980) using 0.04 M sodium phosphate,
pH 7.0 as a transfer buffer. Transferred proteins were visual-
ised by amidoblack 10 B (Syu & Kahan, 1987) or by col-
loidal silver (Kovarik et al., 1987) for higher sensitivity.
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Immunodetection
The nitrocellulose sheet was cut into 0.5 cm wide strips. Each
strip carried a large quantity of MMTV proteins (approx-
imately 100 tg) to increase the sensitivity of the immuno-
detection. Strips were incubated for 2 h at 25°C in BLOTTO
(5% non-fat dry milk in 50 mM Tris-HCl, pH 8.2, 2 mM
CaCI2, 80 mM NaCl, 0.2% Triton X-100, 10-5% merthiolate
and 0.01% Antifoam) to block non-specific antibody bin-
ding. All human test sera were diluted 1: 100 in BLOTTO.
Hyperimune sera were used in dilutions from 1:1000 to
1:200. Strips were incubated with diluted sera overnight at
4°C. After the incubation, strips were washed 3 x with TEN
buffer (50 mM Tris-HCI, pH 7.4, 5 mM EDTA, 0.15 M NaCl,
0.05% Tween 20). After 30 min of washing 1251 Protein-A
was added to final activity of 5.0 x 106 c.p.m. ml1' of
BLOTTO and incubated for 60 min at 25°C. The strips were
then washed several times with TEN, dried, mounted and
autoradiographed (13-max films, Amersham). In the case of
mouse or goat antibodies, the appropriate horse-radish per-
oxidase-labelled anti-immunoglobulin (DAKO) was used and
the colour was developed by diaminobenzidine /H202 reac-
tion.
Radiolabelling of Protein-A
Protein-A was labelled by Na'251 (Amersham) by the chlor-
amine T method (Greenwood et al., 1963).
Antisera to viral proteins
Antiserum to whole MMTV was obtained by multiple immu-
nisation of rabbits by Tween-ether disrupted virus. Primary
immunisation was in complete Freund's adjuvant, followed
boosters in incomplete adjuvant. Monospecific antiserum to
p27 MMTV was prepared in rabbit by immunisation with
polyacrylamide slices cut from SDS-PAGE. Antiserum to
Mason-Pfizer monkey virus (MPMV) was donated by the
Division of Cancer Cause and Prevention, NCI, Bethesda.
Mouse monoclonal antibody recognising mouse actin was
obtained from Amersham, England.
Results
Specific reactions of human sera wvith MMTVproteins
We have analysed 300 samples of human sera for the pre-
sence of antibodies to MMTV proteins using the immuno-
blotting assay (Table I). Various sera from cancer patients
and healthy controls reacted with p27, p14, p30 and gp52.
Most predominant were the reactions to p30 and p14 respec-
tively, but reactions of sera recognising p30 only were weak
and were not detected when using lower quantities of antigen
(i.e. 30yg of viral proteins per 0.5 cm strip). Some sera
containing antibodies to p14 and p30 also recognised a
42 kDa cellular contaminant of the virus. Immunoblots of
human sera with the highest titres against MMTV proteins
are shown in Figure 1. Immunodetections were performed on
the strips cut from the same blot. Reactions of human sera in
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Figure 1 Immunoblotting patterns in serum samples reacting
with MMTV proteins. Lane 1: amidoblack staining of transferred
MMTV proteins. Lane 2: serum from patient with acute myelo-
genous leukemia (1:100 dilution). Lane 3: serum from patient
with malignant melanoma (1:100 dilution). Lanes 4,5: sera from
healthy controls (1:100 dilution). Lane 6: rabbit anti-MMTV
serum (1:1,000 dilution). Lane 7: preimmune serum (1:100 dilu-
tion). Lane 8: goat anti-MPMV serum (1:200 dilution).
Table I Specific reactions of human sera to MMTV structural proteins
Diagnosis
Breast cancer
Colon carcinoma
Malignant melanoma
Acute myelogenous leukaemia
Acute lymphocytic leukaemia
Non-Hodgkin's lymphoma
Hodgkin's disease
AIDS patients
Systemic lupus erythematosus
Multiple sclerosis
Psoriasis
Pregnant women
Healthy controls
male
female
Total
No. ofsera reacting with MMTV
No.of sera
tested p27 pl4U p30 gp52
60
7
43
20
34
18
6
4
6
4
2
6
30
60
300
I
0
1 (I)b
0
0
1 (1)
0
0
0
0
0
0
2
0
3 (2)
0
0
0
0
l
0
0 3 (1)
0 5 (1)
3 (2) 16 (4)
4
0
3 (2)
1
1
0
0
1
1
0 0
5 (1)
6 (1)
22 (4)
2
0
1
1 (1)
0
1 (1)
0
0
0
0
0
0
1 (1)
0
6 (3)
"Sera positive withp14 always reacted withp30. bNumbers in parentheses are sera with
strong signal in immunoblotting.
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Figure 1 revealed clear bands in the positions of viral glycop-
rotein gp52 (lane 2), major core protein p27 (lane 3), ribo-
nucleoprotein p14 and a transframe protein p30 (lane 4). The
reaction to p30 only was too faint to permit clear photo-
graphic reproduction (Figure 1, lane 5). To confirm the
sensitivity and specificity of the immunoassay antisera to
MMTV, MPMV, preimmune and normal rabbit sera were
tested. Rabbit hyperimmune serum to whole MMTV reacted
strongly with plO, p27, p14, p30 and glycoproteins gp36 and
gp52 (Figure 1, lane 6). Cross-reactivity between MMTV and
MPMV is revealed by antiserum to MPMV recognising p30
and ribonucleoprotein p14 MMTV (Figure 1, lane 8). Preim-
mune and normal rabbit sera did not react. Positive sera
were tested for reactivity to other retroviruses such as BLV,
Ra-MuLV and AMV. None of them reacted. In contrast
some other human sera reacted with major core protein of
Ra-MuLV (data not shown). All reactive antibodies to
MMTV proteins are of IgG class since no reactivity was
observed when an anti human IgM peroxidase conjugate was
used as the second antibody.
Reactions ofhuman sera with non-viralproteins in MMTV
preparations
Frequent reactions of human sera were observed with non-
viral proteins. These reactions were more frequent when less
pure preparations were used for immunoblotting. Most pre-
dominant was reaction in 42 kDa region (Figure 2a, lane 3).
Reaction with gag precursor proteins was excluded since
monospecific antiserum to the major core protein p27 did not
react with proteins of this size (Figure 2a, lane 4). Cellular
actin has a molecular weight of 42 kDa and therefore stain-
ing could result from an autoimmune reaction directed
against actin. The following experiment, however, does not
favour this hypothesis. A monoclonal antibody to actin de-
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Figure 2 Immunoblotting assay of two different MMTV sam-
ples. Blot a: MMTV of high purity. Blot b: MMTV contaminated
with cellular debris. Lane 1: non-immunological staining (a: col-
loidal silver, b: amidoblack). Lane 2: anti-actin mouse monoc-
lonal antibody (1:1,000 dilution). Lane 3: serum from patient
with breast cancer (1:100 dilution). Lane 4: rabbit monospecific
serum anti p27 MMTV (1:800 dilution).
tects actin as the upper band in the 42 kDa region; in con-
trast the reaction of human sera is with the lower band.
Furthermore when a less pure MMTV preparation was used
as the antigen, a broad band was observed when anti-actin
monoclonal antibody was used (Figure 2b, lane 2). Human
sera, however, reacted with a protein migrating as a sharp
band. The less pure isolate of MMTV was obtained from cell
culture media with a high content of cellular debris. The
purity of the virus is highly dependent on the state of the
producing cell culture. However, even the most pure ret-
roviral preparations always contain cellular proteins as con-
taminants and actin is a well known example.
The described reactions of human sera with cellular con-
taminants of the virus show the advantages of immunoblot
or RIP over ELISA and CIF for screening of specific anti-
bodies to viral proteins. The latter two methods may provide
false positive results due to the reactions with 42 kDa protein
and other cellular contaminants of the virus.
Discussion
Our study revealed the presence of antibody reactions with
p27, p14, p30 and gp52 MMTV proteins in human sera by
Western blot analysis. Reactions with p30 and p14 (about
7% with p30 and 5% with p14 of all sera tested) were most
frequent. These two antigens were recognised by sera of
cancer patients and healthy controls. The structural protein
p30 has recently been reported to be a transframe protein
with its aminoterminus containing the entire sequence of the
ribonucleoprotein p14 and carboxyterminus encoded by the
protease open reading frame (Hizi et al., 1987). Interestingly
the incidence of the reactions with these two antigens is
relatively high in healthy controls (about 12% for p30 and
9% for p14). We found that the titre remained unchanged
during a 2-year period in one healthy blood donor. We
suggest that the reactions to p30 and p14 are not connected
with any pathological conditions and that natural antibodies
spontaneously appearing in sera without any known anti-
genic stimulus may be responsible for these reactivities. Reac-
tions with major core protein p27 and envelope glycoprotein
gp52 predominated in sera of cancer patients. Sera of p27
and gp52 specificities reacted with no other protein in these
experiments.
It was reported that antibodies to MMTV antigens can be
detected in sera of more than 20% of breast cancer patients
using ELISA or CIF techniques (Witkin et al., 1980; Day et
al., 1981; Tomana et al., 1981; Holder & Wells, 1983). Our
results show that the incidence of specific antibodies to
MMTV proteins is much lower and no increased frequency is
observed in breast cancer sera. In contrast, human sera
especially those of breast cancer patients detected a cellular
contaminant of the virus in the 42 kDa region. We suggest
that the previously published increased levels of antibodies to
MMTV in breast cancer sera are the result of reactions with
cellular contaminants of the virus rather than with viral
proteins themselves.
The humoral response might be directed to exogenous
agents or to self antigens. In our opinion the reactions of
human sera to MMTV proteins are probably of autoimmune
origin. Exposure to an MMTV-like agent is improbable
because (a) low frequencies of reactions to p27 and gp52
(about 2% for p27 and 3% for gp52 of all cancer patients
sera tested and (b) we did not find any sera containing both
types of antibodies i.e. to p27 and gp52. The autoimmune
response might be directed against the product of activated
endogenous retrovirus related to MMTV or against some
cellular protein that shares partial sequence homology with
viral proteins. The latter situation has been described for
autoimmune reactions of sera from patients with mixed con-
nective tissue disease recognising the 70 kDa protein of
U,snRNP immunologically cross-reactive with p30 MuLV
(Query & Keene, 1987). The conclusions can be summarised
as follows: (I) specific antibodies recognising MMTV pro-
teins sporadically appear in human sera. (2) Most frequentANTIBODIES TO MMTV IN HUMANS 575
reactivities are to transframe protein p30 and ribonucleop-
rotein p14. These reactions occur in sera of cancer patients
and healthy controls. (3) Specific reactions to major core
protein p27 and envelope glycoprotein gp52 were observed
predominantly in sera of cancer patients but their prevalence
is low. (4) Reactions with 42 kDa cellular contaminant of the
virus occur more frequently than specific reactions to MMTV
proteins and they might be responsible for false positivities in
ELISA and CIF assays. (5) No direct correlation between the
incidence of malignant disease and the presence of specific
antibodies to MMTV proteins can be found due to their low
incidence. Nevertheless, their sporadic occurrence may help
further search for antigens circumstantially expressed during
carcinogenesis.
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